Premium
Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature—A report from the SIOP Renal Tumor Study Group
Author(s) -
Hol Janna A.,
den HeuvelEibrink Marry M.,
Graf Norbert,
PritchardJones Kathy,
Brok Jesper,
Tinteren Harm,
Howell Lisa,
Verschuur Arnauld,
Bergeron Christophe,
Kager Leo,
Catania Serena,
Spreafico Filippo,
MavinkurveGroothuis Annelies M. C.
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26849
Subject(s) - irinotecan , medicine , wilms' tumor , oncology , cancer , colorectal cancer
Abstract While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan‐containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate‐risk (CR and PR) and blastemal‐type histologies (PR). Two patients were alive at last follow‐up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.